title: Persistence of HIV-1 transmitted drug resistance mutations.
abstract: There are few data on the persistence of individual human immunodeficiency virus type 1 (HIV-1) transmitted drug resistance (TDR) mutations in the absence of selective drug pressure. We studied 313 patients in whom TDR mutations were detected at their first resistance test and who had a subsequent test performed while ART-naive. The rate at which mutations became undetectable was estimated using exponential regression accounting for interval censoring. Most thymidine analogue mutations (TAMs) and T215 revertants (but not T215F/Y) were found to be highly stable, with NNRTI and PI mutations being relatively less persistent. Our estimates are important for informing HIV transmission models.
authors.affiliation: Medical Research Council Clinical Trials Unit, London, United Kingdom.
authors.forename: Hannah
authors.initials: H
authors.lastname: Castro
authors.forename: Deenan
authors.initials: D
authors.lastname: Pillay
authors.forename: Patricia
authors.initials: P
authors.lastname: Cane
authors.forename: David
authors.initials: D
authors.lastname: Asboe
authors.forename: Valentina
authors.initials: V
authors.lastname: Cambiano
authors.forename: Andrew
authors.initials: A
authors.lastname: Phillips
authors.forename: David T
authors.initials: DT
authors.lastname: Dunn
mesh_terms: D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D008297:Male; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents
keywords: HIV-1; mutations; persistence; resistance; transmitted
references.citation: AIDS. 2011 Mar 27;25(6):843-50
references.pmid: 21192233
references.citation: J Virol. 2008 Jun;82(11):5510-8
references.pmid: 18353964
references.citation: Lancet Infect Dis. 2011 May;11(5):363-71
references.pmid: 21354861
references.citation: PLoS One. 2009;4(3):e4724
references.pmid: 19266092
references.citation: J Antimicrob Chemother. 2011 Jul;66(7):1467-80
references.pmid: 21502281
references.citation: J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):309-15
references.pmid: 19734799
references.citation: J Virol. 1999 May;73(5):3744-52
references.pmid: 10196268
references.citation: Sci Rep. 2012;2:320
references.pmid: 22432052
references.citation: J Virol. 2007 Mar;81(6):3037-41
references.pmid: 17192300
references.citation: Antivir Ther. 2006;11(2):173-8
references.pmid: 16640098
references.citation: AIDS. 2004 Aug 20;18(12):1683-9
references.pmid: 15280779
references.citation: AIDS. 2007 May 11;21(8):1035-9
references.pmid: 17457098
references.citation: J Infect Dis. 2007 Feb 1;195(3):399-409
references.pmid: 17205479
references.citation: J Infect Dis. 2011 Apr 15;203(8):1174-81
references.pmid: 21451005
references.citation: J Virol. 1998 May;72(5):3520-3
references.pmid: 9557630